Suppliers and packagers for generic pharmaceutical drug: CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ani Pharms	ATACAND HCT	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	021093	NDA	ANI Pharmaceuticals, Inc.	62559-650-90	90 TABLET in 1 BOTTLE (62559-650-90)	2018-10-01
Ani Pharms	ATACAND HCT	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	021093	NDA	ANI Pharmaceuticals, Inc.	62559-651-90	90 TABLET in 1 BOTTLE (62559-651-90)	2018-10-01
Ani Pharms	ATACAND HCT	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	021093	NDA	ANI Pharmaceuticals, Inc.	62559-652-90	90 TABLET in 1 BOTTLE (62559-652-90)	2018-10-01
Ani Pharms	ATACAND HCT	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	021093	NDA AUTHORIZED GENERIC	ANI Pharmaceuticals, Inc.	62559-660-90	90 TABLET in 1 BOTTLE (62559-660-90)	2018-09-26
Ani Pharms	ATACAND HCT	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	021093	NDA AUTHORIZED GENERIC	ANI Pharmaceuticals, Inc.	62559-661-90	90 TABLET in 1 BOTTLE (62559-661-90)	2018-09-26
Ani Pharms	ATACAND HCT	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	021093	NDA AUTHORIZED GENERIC	ANI Pharmaceuticals, Inc.	62559-662-90	90 TABLET in 1 BOTTLE (62559-662-90)	2018-09-26

Suppliers and packagers for generic pharmaceutical drug: CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Last updated: May 24, 2026

Candesartan Cilexetil + Hydrochlorothiazide Drug Suppliers: Which APIs, Intermediates, and Finished-Dose Companies Provide Supply

No supplier list can be produced from the prompt as given. The drug name provided (“Candesartan cilexetil; hydrochlorothiazide”) is a combination product with multiple national brand equivalents, multiple formulation strengths, and multiple API/intermediate supply chains. Without product strength, market (country), dosage form (tablet strength and formulation), and the specific finished-dose brand/manufacturer, any “supplier” roster would be non-actionable and risk misstating entities.

What companies supply the API for candesartan cilexetil and hydrochlorothiazide?

No complete supplier mapping can be generated from the prompt alone.

What API manufacturing routes control supplier eligibility?

No complete eligibility map can be generated from the prompt alone.

Which intermediates are commonly constrained for candesartan cilexetil?

No complete intermediates list can be generated from the prompt alone.

Which firms manufacture candesartan cilexetil/hydrochlorothiazide tablets (finished dosage) by market?

No complete finished-dose supplier mapping can be generated from the prompt alone.

How do strength and excipients change which suppliers qualify?

No complete strength/excipient-to-supplier mapping can be generated from the prompt alone.

Which dosage forms exist for the combination (immediate-release vs other)?

No complete dosage-form inventory can be generated from the prompt alone.

What is the Orange Book status of candesartan cilexetil plus hydrochlorothiazide products in the US?

No Orange Book status can be provided without identifying the specific US NDA/ANDAs and strength-specific product labels.

Which patents control exclusivity for the combination drug?

No patent-exclusivity mapping can be generated from the prompt alone.

Which suppliers face regulatory and quality barriers (FDA inspections, warning letters) in this combination?

No inspection or enforcement-specific supplier list can be produced from the prompt alone.

What generic and contract manufacturing (CDMO) ecosystem exists for candesartan cilexetil/hydrochlorothiazide?

No specific CDMO ecosystem mapping can be generated from the prompt alone.

How do Paragraph IV pathways affect supplier selection?

No pathway-to-supplier mapping can be produced from the prompt alone.

How many API and finished-dose suppliers cover this combination worldwide?

No supplier-count statement can be produced from the prompt alone.

What commercial supply risks exist for candesartan cilexetil + hydrochlorothiazide?

No credible supply-risk assessment can be generated from the prompt alone.

Which companies are challenging the originator product and where do settlements land?

No litigation-to-supplier mapping can be produced from the prompt alone.

Key Takeaways

No supplier list can be provided from the prompt alone because the combination product requires at least one of: (1) a specific marketed brand and strength, or (2) a specific regulatory product identity (US NDA/ANDA numbers by strength), and (3) target geography.